EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Gia Han Le iD, Sabrina Wong, Danica E Johnson, Diana K Orsini iD, Yang Jing Zheng, Kayla M Teopiz, Christine E Dri, Joshua D Rosenblat iD, Roger S McIntyre iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Gia Han Le und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT2B, Antidepressive Agents, Serotonin 5-HT2 Receptor Agonists, Major Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and clinical literature identified via PubMed and OVID (MEDLINE, Embase, AMED, PsychINFO) databases from inception to September 2025, supplemented by manual searches. Evidence converges that peripheral 5‐HT2BR agonism is mechanistically linked to valvular heart disease (VHD) through mitogenic/profibrotic signaling in valve tissue, consistent with historical signals for anorectic agents (e.g., fenfluramine) and ergot‐derived dopamine agonists, with supportive but limited data for 3,4‐methylenedioxymethamphetamine (MDMA). Classical serotonergic psychedelics bind 5‐HT2BRs; therefore, while contemporary dosing regimens are intermittent, cumulative exposure risks remain insufficiently characterized. Conversely, central 5‐HT2BR signaling appears bidirectional wherein astrocytic 5‐HT2BR activation under sustained serotonergic tone may support metabolic and plasticity programs, whereas neuronal 5‐T2BR antagonism can normalize mesolimbic dopamine output and enhance medial prefrontal glutamatergic activity. Clinically, several approved antidepressant adjuncts (e.g., aripiprazole, brexpiprazole, cariprazine) display 5‐HT2BR antagonism or inverse agonism and improve depressive symptoms without observed valvular signals in trials. The 5‐HT2BR represents a tractable augmentation target for TRD provided that peripheral agonism is rigorously avoided. Consistent with evolving scientific and regulatory safety frameworks, we propose advancing centrally selective, periphery‐sparing 5‐HT2BR antagonists into biomarker‐anchored early cardiac monitoring and preclinical exclusion of valve‐cell 5‐HT2BR agonism. This framework integrates central efficacy with defined safety boundaries, guiding development of mechanistically informed antidepressant therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Serotonin, 5-HT2BAntidepressive AgentsSerotonin 5-HT2 Receptor AgonistsMajor Depressive DisorderDepressive Disorder, Treatment-ResistantSerotonin 5-HT2 Receptor AntagonistsHumansAnimals

Substanzen

Receptor, Serotonin, 5-HT2BAntidepressive AgentsSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonists

Autor:innen und Institutionen

  • Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Poul Hansen Family Centre for Depression, University Health Network, Toronto, Ontario, Canada.
  • Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
  • Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Gia Han Le, Diana K Orsini, Joshua D Rosenblat, Roger S McIntyre

Zitieren

APA

Le, G. H., Wong, S., Johnson, D. E., Orsini, D. K., Zheng, Y. J., Teopiz, K. M., Dri, C. E., Rosenblat, J. D., & McIntyre, R. S. (2026). The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70344

Vancouver

Le GH, Wong S, Johnson DE, Orsini DK, Zheng YJ, Teopiz KM, et al. The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70344

BibTeX
@article{Le2026,
  author = {Le, Gia Han and Wong, Sabrina and Johnson, Danica E and Orsini, Diana K and Zheng, Yang Jing and Teopiz, Kayla M and Dri, Christine E and Rosenblat, Joshua D and McIntyre, Roger S},
  title = {The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70344}
}
Kostenlos starten →